ES2128846T3 - Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales. - Google Patents

Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales.

Info

Publication number
ES2128846T3
ES2128846T3 ES96909200T ES96909200T ES2128846T3 ES 2128846 T3 ES2128846 T3 ES 2128846T3 ES 96909200 T ES96909200 T ES 96909200T ES 96909200 T ES96909200 T ES 96909200T ES 2128846 T3 ES2128846 T3 ES 2128846T3
Authority
ES
Spain
Prior art keywords
fumagilol
derivatives
intestinal infections
sub
drugs intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909200T
Other languages
English (en)
Spanish (es)
Inventor
Jean-Michel Molina
Francis Derouin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Sanofi SA
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA, Assistance Publique Hopitaux de Paris APHP filed Critical Sanofi SA
Application granted granted Critical
Publication of ES2128846T3 publication Critical patent/ES2128846T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES96909200T 1995-03-27 1996-03-26 Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales. Expired - Lifetime ES2128846T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27

Publications (1)

Publication Number Publication Date
ES2128846T3 true ES2128846T3 (es) 1999-05-16

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909200T Expired - Lifetime ES2128846T3 (es) 1995-03-27 1996-03-26 Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales.

Country Status (25)

Country Link
US (1) US5900431A (OSRAM)
EP (1) EP0817626B1 (OSRAM)
JP (1) JP3260378B2 (OSRAM)
KR (1) KR100286920B1 (OSRAM)
CN (1) CN1072485C (OSRAM)
AP (1) AP646A (OSRAM)
AT (1) ATE172641T1 (OSRAM)
AU (1) AU706161B2 (OSRAM)
CA (1) CA2216623C (OSRAM)
CZ (1) CZ286821B6 (OSRAM)
DE (1) DE69600879T2 (OSRAM)
DK (1) DK0817626T3 (OSRAM)
EA (1) EA000150B1 (OSRAM)
ES (1) ES2128846T3 (OSRAM)
FR (1) FR06C0014I2 (OSRAM)
HU (1) HU224028B1 (OSRAM)
IS (1) IS2048B (OSRAM)
NO (1) NO315968B1 (OSRAM)
NZ (1) NZ304906A (OSRAM)
OA (1) OA10515A (OSRAM)
PL (1) PL183378B1 (OSRAM)
SK (1) SK283883B6 (OSRAM)
TR (1) TR199701048T1 (OSRAM)
UA (1) UA41446C2 (OSRAM)
WO (1) WO1996030010A2 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
DK1156829T3 (da) 1999-02-26 2007-09-10 Sanofi Aventis Stabil formulering indeholdende fumagillin
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
EA020251B1 (ru) * 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
WO2010009374A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
JP5827239B2 (ja) 2010-01-08 2015-12-02 ザフゲン，インコーポレイテッド フマギロール型化合物並びにその製造方法及び使用方法
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
BR112013013411A2 (pt) 2010-11-29 2016-09-13 Zafgen Inc tratamento de obesidade usando administração não diária de 6-0-(4-dimetilaminoetxi) cinamoil fumagilol
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
EP2683706B1 (en) 2011-03-08 2018-02-21 Zafgen, Inc. Oxaspiro [2.5]octane derivatives and analogs
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
JP5941981B2 (ja) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその製造および使用方法
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
WO2013169727A1 (en) 2012-05-07 2013-11-14 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
KR20150013222A (ko) 2012-05-08 2015-02-04 자프겐 인크. Metap2 저해제를 이용한 시상하부 비만의 치료
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
EP0541716A1 (en) * 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
SK130797A3 (en) 1998-03-04
NO974466L (no) 1997-09-26
EA000150B1 (ru) 1998-10-29
IS4557A (is) 1997-09-11
KR19980703271A (ko) 1998-10-15
NO974466D0 (no) 1997-09-26
FR06C0014I1 (OSRAM) 2006-11-17
HUP9801220A3 (en) 2001-10-29
HUP9801220A2 (hu) 1999-09-28
CN1179715A (zh) 1998-04-22
CA2216623A1 (en) 1996-10-03
HU224028B1 (hu) 2005-05-30
AU5278696A (en) 1996-10-16
DE69600879T2 (de) 1999-06-02
PL322470A1 (en) 1998-02-02
WO1996030010A2 (fr) 1996-10-03
CN1072485C (zh) 2001-10-10
EA199700267A1 (ru) 1998-04-30
US5900431A (en) 1999-05-04
ATE172641T1 (de) 1998-11-15
EP0817626A2 (fr) 1998-01-14
CA2216623C (en) 2005-05-31
IS2048B (is) 2005-09-15
SK283883B6 (sk) 2004-04-06
AU706161B2 (en) 1999-06-10
CZ304997A3 (en) 1997-12-17
JP3260378B2 (ja) 2002-02-25
CZ286821B6 (en) 2000-07-12
AP9701092A0 (en) 1997-10-31
NO315968B1 (no) 2003-11-24
NZ304906A (en) 1999-06-29
DK0817626T3 (da) 1999-07-12
EP0817626B1 (fr) 1998-10-28
PL183378B1 (pl) 2002-06-28
OA10515A (fr) 2002-04-24
UA41446C2 (uk) 2001-09-17
KR100286920B1 (ko) 2001-04-16
FR06C0014I2 (OSRAM) 2006-12-29
AP646A (en) 1998-04-27
MX9707150A (es) 1998-07-31
TR199701048T1 (xx) 1998-01-21
DE69600879D1 (de) 1998-12-03
WO1996030010A3 (fr) 1996-11-28
JPH11506421A (ja) 1999-06-08

Similar Documents

Publication Publication Date Title
ES2128846T3 (es) Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales.
PA8452001A1 (es) Derivados de macrolidos c-4" sustituidos
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
ES2018111A6 (es) Procedimiento de preparacion de derivados de 4h-1-benzopiran-4-ona o sus sales.
AR034691A1 (es) Composiciones farmaceuticas de administracion oral, que contiene un inhibidor de lipasa gastrointestinal, el comprimido masticable y la galleta que los comprende
AR005458A1 (es) 2-oxo-y 2-tio-1,2-dihidroquinolinil-oxazolidinonas, procedimiento para su produccion, el uso de las mismas para la produccion de un medicamento ymedicamentos que los contienen
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ES2081397T3 (es) O-metil derivados de azitromicina a, procedimiento y productos intermedios para su preparacion, y uso de los mismos en la preparacion de productos farmaceuticos.
UY26782A1 (es) Derivados del benzotiazol
ES2161290T3 (es) Derivados de quinazolina.
ES2184960T3 (es) Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
MX173630B (es) Derivados de aminoacido, procedimiento para su preparacion y su preparacion y medicamento que los contiene
MX9305566A (es) Derivados de urea ciclicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2106463T3 (es) 3-desoxi-oligosacaridos, procedimientos para su obtencion y composiciones farmaceuticas que los contienen.
CO4970795A1 (es) Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
TR199801082T2 (xx) Fosfonokarbiksilik asitlerin yeni fosfolipid t�revleri, bunlar�n �retimi, bunun yan�s�ra bunlar�n antiviral farmas�tik maddeler olarak kullan�m�.
MX9302459A (es) Derivados imino ciclicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 817626

Country of ref document: ES